Ascendis Pharma (ASND) Gets EU Panel Backing, Is The Stock Still Cheap?

Ascendis Pharma (NasdaqGS:ASND) stock is back in focus after a positive opinion from the European Medicines Agency’s CHMP for TransCon CNP in pediatric achondroplasia, with an EU marketing decision expected in the fourth quarter of 2026.

Set against this regulatory progress, Ascendis Pharma’s recent price action has been softer. The share price is down 4.85% over 30 days and 10.53% over 90 days, contributing to an 8.20% year to date share price decline from the current US$225.25 level.

Scan beyond Ascendis Pharma and line up other biopharma opportunities reacting to fresh catalysts with our hand picked 33 healthcare AI stocks.

Ascendis Pharma now trades at a sizeable discount to both analyst targets and an intrinsic value estimate, even after the recent pullback. Is that gap in caution well placed, or starting to look excessive as fundamentals evolve?

Most Popular Narrative: 27% Undervalued

Ascendis Pharma’s most followed narrative pegs fair value at about $309 per share, well above the recent $225.25 close. This frames the current discount as sizeable against the platform and pipeline expectations embedded in that model.

Regulatory and commercial rollout of TransCon CNP in achondroplasia, including potential U.S. approval and ex U.S. launches, targets an area of clear unmet need where once weekly dosing and benefits beyond linear growth are a focus. This can support incremental revenue growth and scale benefits on selling and marketing expenses.

See why 5 investors see Ascendis Pharma as 27% undervalued.

Result: Fair Value of $309 (UNDERVALUED)

Still, the Ascendis Pharma story can change quickly if YORVIPATH uptake stalls or if TransCon CNP timelines, labels, or real world adoption fall short of expectations.

Find out about the key risks to this Ascendis Pharma narrative.

Next Steps

Does this chorus of risks and rewards around Ascendis Pharma match your own read of the story, or feel out of step with the data in front of you? Take a closer look at both sides of the argument and pressure test the bullish and cautious angles for yourself with 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Ascendis Pharma?

Do not stop with Ascendis Pharma. Use the Simply Wall St screener to spot fresh opportunities that fit your goals before they move without you.

• Target resilient balance sheets and steady fundamentals with a curated list of solid balance sheet and fundamentals (25 results) that keeps financial strength front and center.
• Hunt for potential value gaps by scanning a focused 33 high quality undervalued stocks that filters for quality alongside pricing pressure.
• Anchor your income plan by reviewing a hand picked 8 dividend fortresses built around higher yields and robust payout support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com